Bartlett & Co Wealth Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-68,882
Closed -$7.97M 1285
2023
Q3
$7.97M Sell
68,882
-4,963
-7% -$533K 0.14% 106
2023
Q2
$7.59M Buy
73,845
+66,345
+885% +$7M 0.13% 112
2023
Q1
$819K Hold
7,500
0.02% 243
2022
Q4
$854K Sell
7,500
-2,500
-25% -$208K 0.02% 239
2022
Q3
$619K Hold
10,000
0.01% 254
2022
Q2
$798K Sell
10,000
-1,386
-12% -$131K 0.02% 238
2022
Q1
$1.2M Buy
11,386
+386
+4% +$37.6K 0.02% 215
2021
Q4
$1.19M Hold
11,000
0.02% 220
2021
Q3
$1.2M Buy
+11,000
New +$1.14M 0.02% 196

Other funds holding HZNP

Bartlett & Co Wealth Management's HZNP Position: Q4 2023 in Review

Bartlett & Co Wealth Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 68,882 shares — an estimated $7.97M sold.

Bartlett & Co Wealth Management first reported a position in HZNP in Q3 2021 and held it in 9 quarters. The position peaked at $7.97M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Bartlett & Co Wealth Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Bartlett & Co Wealth Management sold 68,882 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $7.97M.
  • Bartlett & Co Wealth Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2021 and held it in 9 quarters.
  • Bartlett & Co Wealth Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $7.97M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Bartlett & Co Wealth Management's 13F filing for Q4 2023, filed 14 Feb 2024.